Kabra Drugs to scout multiple acquisitions, targeting scale, portfolios, and distribution depth

Board greenlights an acquisition-led growth path

Kabra Drugs Ltd has initiated a formal process to assess several acquisition opportunities across pharmaceuticals and allied healthcare segments. The strategy seeks to build scale in branded generics and specialty formulations, add backward integration in APIs/intermediates, and widen reach in institutional and retail channels. The company indicated that targets will be vetted for regulatory compliance, audited financials, and integration feasibility, with priority on assets that enhance manufacturing utilization and margin profile. A dedicated committee will oversee diligence, valuation, and financing structures, balancing growth with governance and capital discipline.

 

Key highlights

Sources: BSE corporate filings; NSE announcements; MarketScreener company updates; The Economic Times (company disclosures).